AVRO Key Statistics, Chart & Performance
The current stock price of AVRO is 1.4 USD. In the past month the price increased by 1.45%. In the past year, price increased by 52.14%.
AVRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AVRO. When comparing the yearly performance of all stocks, AVRO is one of the better performing stocks in the market, outperforming 92.57% of all stocks.
AVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVRO. AVRO has a great financial health rating, but its profitability evaluates not so good.
AVRO Financial Highlights
Over the last trailing twelve months AVRO reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 49.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 32.82% | ||
| ROE | 34.11% | ||
| Debt/Equity | 0 |
AVRO Forecast & Estimates
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4.
AVRO Ownership
About AVRO
Company Profile
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Company Info
AVROBIO INC
100 Technology Square, 6th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Geoff MacKay
Employees: 78
Phone: 16179148420
AVROBIO INC / AVRO FAQ
What does AVRO do?
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
What is the stock price of AVROBIO INC today?
The current stock price of AVRO is 1.4 USD. The price decreased by -1.41% in the last trading session.
Does AVROBIO INC pay dividends?
AVRO does not pay a dividend.
How is the ChartMill rating for AVROBIO INC?
AVRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for AVROBIO INC?
AVROBIO INC (AVRO) operates in the Health Care sector and the Biotechnology industry.